Application of demethyleneberberine in preparation of hypolipidemic drug

A technology for desmethylene berberine and a drug is applied in the application field of desmethylene berberine in the preparation of blood lipid-lowering drugs, and can solve the problems of liver toxicity, toxic and side effects, and reduced drug efficacy, and achieve a good reduction in blood lipids. The effect of lipid action

Inactive Publication Date: 2014-07-16
CHINA PHARM UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, although statins and other drugs have good lipid-lowering effects, long-term use may cause toxic side effects such as liver toxicity and rhabdomyolysis, and have a greater impact on drug-metabolizing enzymes in the liver
However, changes in the expression and activity of drug-metabolizing enzymes in the liver may affect the pharmacokinetics of co-administered drugs in vivo, resulting in drug interactions and resulting in reduced drug efficacy or toxic side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of demethyleneberberine in preparation of hypolipidemic drug
  • Application of demethyleneberberine in preparation of hypolipidemic drug
  • Application of demethyleneberberine in preparation of hypolipidemic drug

Examples

Experimental program
Comparison scheme
Effect test

example

[0009] Examples of lipid-lowering effects of demethylene berberine

[0010] C57BL / 6 mice (30, purchased from the Academy of Military Medical Sciences, weighing 18±2 g) were used for the experiment. With AIN93 standard feed (according to calorific value, containing 10% fat, 75.9% carbohydrate, 14.1% protein, 3601 kcal / kg) and standard feeding environment (free eating and drinking, alternate day and night, each 12 hours), adapt Sex feeding for a week. Subsequently, they were randomly divided into 5 groups by body weight, one group continued to be given normal feed, and the other four groups were all given high-fat feed (calculated by calorie value, containing 60% fat, 25.9% carbohydrate, 14.1% protein, and 5018 kcal of heat). / kg) (Nantong Trofe Feed Technology Co., Ltd.), and all rats had free access to drinking water. The above-mentioned 5 groups of animals were fed under the same conditions. Blood was collected at 3 weeks, serum plasma was separated, and total triglyceride ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a hypolipidemic compound demethyleneberberine. The demethyleneberberine is derived from a main in-vivo metabolite of natural medicine berberine. The researches on model animals with hyperlipidemia find that the demethyleneberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

Description

technical field [0001] The present invention relates to desmethylene berberine with lipid-lowering pharmacological effects and its potential clinical application, in particular to desmethylene berberine showing a better lipid-lowering effect on hyperlipidemia model animals, which is expected to be further developed through further Research and development has become a class of innovative drugs for clinical blood lipid lowering and weight loss for obese people. Background technique [0002] Hyperlipidemia is a major risk factor for cardiovascular and cerebrovascular diseases and an important factor that endangers human health. Clinically, although statins and other drugs have good lipid-lowering effects, long-term use may cause toxic side effects such as liver toxicity and rhabdomyolysis, and have a greater impact on drug-metabolizing enzymes in the liver. The changes in the expression and activity of drug-metabolizing enzymes in the liver may affect the in vivo pharmacokine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P3/06A61P3/04A61P3/10A61P3/00
Inventor 阿基业王广基孙润彬马亭费菲肖文璟俞晓忆
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products